Medical marijuana advocates and bureaucrats from regulatory agencies around the world have both been awaiting a statement on the risks and benefits of cannabidiol (CBD) from the World Health Organization's Expert Committee on Drug Dependence (ECDD). Now the assessment on the non-psychoactive cannabinoid is in, and it is encouraging news for those who have been hoping for its removal from Schedule 1, the international designation for drugs with no therapeutic value but high potential for abuse.
Recent comments
9 weeks 6 days ago
15 weeks 4 days ago
26 weeks 4 days ago
27 weeks 4 days ago
29 weeks 1 day ago
29 weeks 4 days ago
29 weeks 6 days ago
34 weeks 2 days ago
35 weeks 3 days ago
35 weeks 3 days ago